Sleep Aids - NAFTA

NAFTA

Highlights

Revenue in the Sleep Aids market amounts to US$2.23bn in 2024. The market is expected to grow annually by 3.58% (CAGR 2024-2029).
In global comparison, most revenue is generated United States (US$2bn in 2024).
In relation to total population figures, per person revenues of US$4.38 are generated in 2024.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureMethodology

The Sleep Aids market in NAFTA is experiencing steady growth due to increasing customer preferences for natural and non-prescription sleep aids.

Customer preferences: Customers in NAFTA countries are increasingly seeking natural and non-prescription sleep aids as they become more conscious of the potential side effects and addictive properties of prescription sleep medications. This shift in consumer preferences is driven by a growing interest in holistic and alternative approaches to health and wellness. Additionally, customers are becoming more informed about the benefits of natural ingredients such as melatonin, valerian root, and chamomile in promoting better sleep.

Trends in the market: One of the key trends in the Sleep Aids market in NAFTA is the rise of herbal and natural sleep aids. These products are gaining popularity as they are perceived to be safer and have fewer side effects compared to prescription medications. Manufacturers are capitalizing on this trend by introducing new products that incorporate natural ingredients and promote a more holistic approach to sleep health. Another trend in the market is the increasing availability of sleep aids in various formats. Traditionally, sleep aids were available in pill or capsule form. However, there is now a wider range of options including gummies, teas, and sprays. This diversification of product formats allows customers to choose the option that best suits their preferences and lifestyle.

Local special circumstances: In the United States, the Sleep Aids market is particularly influenced by the high prevalence of sleep disorders and insomnia. According to the National Sleep Foundation, approximately 50 to 70 million Americans suffer from a sleep disorder, with insomnia being the most common. This high demand for sleep aids is driving the growth of the market in the country. In Canada, the market is driven by the aging population and the increasing awareness of the importance of sleep health. As the Canadian population continues to age, the prevalence of sleep disorders such as sleep apnea and restless legs syndrome is expected to increase. This presents a significant opportunity for sleep aid manufacturers to cater to the needs of this demographic.

Underlying macroeconomic factors: The Sleep Aids market in NAFTA is also influenced by underlying macroeconomic factors. The rising disposable incomes in the region have led to increased spending on health and wellness products, including sleep aids. Additionally, the growing awareness of the importance of sleep in maintaining overall health and well-being is driving the demand for sleep aids. Furthermore, the increasing prevalence of stressful lifestyles and work-related pressures is contributing to the demand for sleep aids. As individuals face higher levels of stress and anxiety, they are more likely to experience difficulty falling asleep or staying asleep. This creates a need for sleep aids to help them achieve a restful night's sleep. In conclusion, the Sleep Aids market in NAFTA is experiencing growth due to customer preferences for natural and non-prescription sleep aids, as well as the increasing availability of sleep aids in various formats. The market is also influenced by local special circumstances such as the high prevalence of sleep disorders in the United States and the aging population in Canada. Underlying macroeconomic factors such as rising disposable incomes and increasing awareness of the importance of sleep health are also driving the growth of the market in the region.

Data coverage:

Data encompasses B2C spend. Figures are based on the OTC Pharmaceuticals market values, representing revenues generated by both product sales which take place exclusively in pharmacies and products which can be purchased elsewhere. Sales by hospitals are not included.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use data from national statistical offices, international institutions, trade associations, and self-medication associations. Next, we use relevant key market indicators and data from country-specific associations, such as consumer healthcare spending, out-of-pocket healthcare expenditure, health system accessibilities, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. Whereas this market covers only OTC drugs, the Statista Pharmaceuticals market covers both OTC and prescription drugs.